These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 33015795)

  • 1. LncRNA WTAPP1 promotes proliferation of laryngeal carcinoma cells through regulating microRNA-592.
    Shi XY; Lin JJ; Ge XJ; Shi Y
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9532-9540. PubMed ID: 33015795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LncRNA SNHG20 promotes the development of laryngeal squamous cell carcinoma by regulating miR-140.
    Li Y; Xu J; Guo YN; Yang BB
    Eur Rev Med Pharmacol Sci; 2019 Apr; 23(8):3401-3409. PubMed ID: 31081112
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LncRNA SNHG14 promotes proliferation of endometrial cancer through regulating microRNA-655-3p.
    Wang GF; Wen LN
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10410-10418. PubMed ID: 33155197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LncRNA TP73-AS1 promotes malignant progression of hepatoma by regulating microRNA-103.
    Ma CX; Gao WC; Tian L
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(11):4713-4722. PubMed ID: 31210297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. LncRNA LINP1 promotes malignant progression of pancreatic cancer by adsorbing microRNA-491-3p.
    Chen AY; Zhang K; Liu GQ
    Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9315-9324. PubMed ID: 33015772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LncRNA UNC5B-AS1 promotes malignant progression of prostate cancer by competitive binding to caspase-9.
    Tan SF; Ni JX; Xiong H
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2271-2280. PubMed ID: 32196578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of lncRNA FEZF1-AS1 in promoting the occurrence and development of oral squamous cell carcinoma through targeting miR-196a.
    Xu L; Hou TJ; Yang P
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6505-6515. PubMed ID: 31378890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA FAL1 promotes the development of oral squamous cell carcinoma through regulating the microRNA-761/CRKL pathway.
    Ye J; Jiao Y
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5779-5786. PubMed ID: 31298329
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LINC00657 promotes malignant progression of oral squamous cell carcinoma via regulating microRNA-150.
    Xu FY; Xu X; Hu XD
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(5):2482-2490. PubMed ID: 32196599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LncRNA MINCR promotes the development of liver cancer by regulating microRNA-107/β-catenin.
    Li H; Yuan R; Wang H; Li C; Wei J
    J BUON; 2020; 25(2):972-980. PubMed ID: 32521894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
    Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA DARS-AS1 regulates microRNA-129 to promote malignant progression of thyroid cancer.
    Zheng W; Tian X; Cai L; Shen YM; Cao QS; Yang JY; Tian GY
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10443-10452. PubMed ID: 31841198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA XIST promotes migration of Wilms' tumor cells through modulation of microRNA-193a-5p.
    Yao FZ; He R; Jiang YC; Hou Y; Qian D
    Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):9889-9898. PubMed ID: 33090392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LncRNA HOXA-AS2 regulates microRNA-216a-5p to promote malignant progression of non-small cell lung cancer.
    Cui TJ; Lin GS; Dai YM; Zheng JP; Chen Z; Chen Q; Zheng Y; Lin X
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(3 Suppl):264-273. PubMed ID: 31389597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA SNHG7 promotes development of breast cancer by regulating microRNA-186.
    Luo X; Song Y; Tang L; Sun DH; Ji DG
    Eur Rev Med Pharmacol Sci; 2018 Nov; 22(22):7788-7797. PubMed ID: 30536320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LINC01551 promotes metastasis of nasopharyngeal carcinoma through targeting microRNA-132-5p.
    Xue MY; Cao HX
    Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3724-3733. PubMed ID: 32329849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA HOTAIR promotes colon cancer development by down-regulating miRNA-34a.
    Peng CL; Zhao XJ; Wei CC; Wu JW
    Eur Rev Med Pharmacol Sci; 2019 Jul; 23(13):5752-5761. PubMed ID: 31298326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LncRNA WTAPP1 promotes cancer cell invasion and migration in NSCLC by downregulating lncRNA HAND2-AS1.
    Zhang L; Jin C; Yang G; Wang B; Hua P; Zhang Y
    BMC Pulm Med; 2020 May; 20(1):153. PubMed ID: 32473628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LncRNA GIHCG regulates microRNA-1281 and promotes malignant progression of breast cancer.
    Fan LY; Shi KY; Xu D; Ren LP; Yang P; Zhang L; Wang F; Shao GL
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(24):10842-10850. PubMed ID: 31858553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA ITGB1 promotes the development of bladder cancer through regulating microRNA-10a expression.
    Dai L; Chai CM; Shen TY; Tian Y; Shang ZQ; Niu YJ
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6858-6867. PubMed ID: 31486485
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.